Protocol Ledger

NCT04157751 · Phase III · COMPLETED

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Interventional Phase III clinical trial protocol NCT04157751 sponsored by Boehringer Ingelheim in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-18 Enrollment: 530 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04157751
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)530 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04157751
Protocol FieldVerified Registry Value
NCT IdentifierNCT04157751
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment530 participants (ACTUAL)
Registered Start Date2020-05-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI